Chief Development Officer · Immunovant, Inc. (IMVT)

Julia Butchko

A named executive officer of Immunovant in every fiscal year CompBrief holds from FY2020 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$3,707,711

Salary $465,000Stock awards $1,472,764Bonus $269,700

FY2020: $7,842,357

3rd of 4 named executive officers at Immunovant by FY2024 total.

4 named officers on file for Immunovant, FY2024

Julia Butchko’s pay file — $29

  • 2 fiscal years of pay, line by line
  • IMVT’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Immunovant’s whole pay program stands against its peers

  • Immunovant’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IMVT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 26, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Julia Butchko’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Julia Butchko compensation by year

Immunovant Summary Compensation Table · all 2 fiscal years held
In US dollars, as Immunovant reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2024
Salary$372,000$465,000
Bonus$148,800$269,700
Stock awards$926,500$1,472,764
Option awards$6,384,856$1,487,281
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$10,201$12,966
Total$7,842,357$3,707,711

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Immunovant, Inc. DEF 14A filed June 26, 2024, accession 0001764013-24-000114, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Immunovant, Inc. filed document, accession 0001764013-24-000114. Every figure is read from that document and cited to the page and table it appears in. Filed June 26, 2024.

$7.8M
$3.7M
FY20
FY24
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU100,188$3,237,074—
RSU70,510$2,278,178—
RSU13,625$440,224—
Option47,775—$17.00
Option13,322—$19.01
Option102,496—$4.99
Option130,081—$14.70

Per the Outstanding Equity Awards at Fiscal Year-End table in Immunovant, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

5 Form 4 lines since the FY2024 proxy (filed June 26, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2024-08-21Sale—2,907$31.84441,079
2024-08-21Sale—120$32.32440,959
2024-07-17Sale—2,698$29.64444,155
2024-07-17Sale—169$30.55443,986
2024-07-09Sale—1,527$28.06446,853

The 5 most recent of 5 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Immunovant’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Peter SalzmannChief Executive Officer$8,552,430
Jay StoutChief Technology Officer$4,039,880
Julia Butchko · this pageChief Development Officer$3,707,711
Eva Renee BarnettFormer Chief Financial Officer$3,338,969

The full Immunovant compensation record

free company brief

This page is one person within Immunovant's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Immunovant proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Immunovant's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Julia Butchko's compensation dossier · One-time report. No refunds.